CONMED Corporation (CNMD)
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
$49.32-0.20%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
Warn: Primary pillar under pressure — Achieve 5.0% to 6.5% organic revenue growth in 2026: FY26 revenue guidance ~+0.7% vs 5.0% target.
CONMED grows revenue about 5% to 6.5% in 2026. Profit per share is expected near $4.38. The company keeps buying back shares and improving leadership. Its valuation is low compared to peers, with a price-to-earnings ratio of 10.7.
Revenue growth is slowing with recent sales down 1.3% year over year. Earnings guidance was softened for 2026. The market is uncertain about management's ability to meet growth targets. Risks include weaker demand and margin pressure.
The stock price is about 53% below our valuation level, reflecting cautious expectations. Analysts expect roughly 3% revenue growth, which is below management's 5% to 6.5% growth target. Our view is more optimistic on growth and profit.
Breaks if: no share buybacks announced or material reduction in buyback activity
Breaks if: EPS guidance midpoint falls below $4.3 for FY26
Breaks if: organic revenue growth falls below 3% in FY26
Focus on organic constant currency revenue growth excluding gastroenterology product sales as part of portfolio optimization.
Stated as a priority in 2 of last 2 quarters. The company reported 6.0% organic constant currency net sales growth in 2026-Q2 and updated full-year 2026 guidance to expect 5.0% to 6.5% organic growth excluding gastroenterology products. The trajectory is delivering consistent growth aligned with management's stated target.
“Net sales increased 6.0% on an organic constant currency basis excluding GI product offerings.”
“The Company now expects year-over-year organic constant currency revenue growth of approximately 5.0% to 6.5%.”
Breaks if: PE ratio rises above 20 without earnings growth justification
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on organic revenue growth and high-margin products. The current thesis state is intact, supported by recent earnings performance and management's guidance.
The valuation is considered cheap compared to peers, with a slight expectations gap indicating that the market may not fully reflect the company's growth potential. The current pricing suggests a justified valuation without significant fragility.
Fundamentals are likely to show robust earnings quality, with management aiming for organic revenue growth of 5.0% to 6.5% in 2026. However, there is elevated risk due to potential economic downturns affecting the healthcare sector.
The thesis hinges on management's ability to maintain guidance and deliver on growth targets, as well as the performance of sector bellwethers that could influence overall market sentiment. Additionally, any negative shifts in economic indicators could pose risks.
Overall, CNMD's outlook for the next 1 to 3 years appears stable, but it faces risks that could impact its performance. Not investment advice.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The latest earnings beat supports the thesis. However, achieving 5.0% to 6.5% organic revenue growth in 2026 is under threat. Regulatory changes could enhance growth potential in the surgical portfolio.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.